Literature DB >> 12840878

The effects of lower intensity anticoagulation therapy on coagulation system in patients with mechanical prosthetic valves.

X Du1, K Zhang, Z Hu, H Lan, J Luo, Y Jin.   

Abstract

To evaluate the effect of lower intensity anticoagulation therapy in patients with mechanical prosthetic valves, laboratory-based hematological assays including prothrombin time (PT), activity of factor X, antithrombin III (AT III), D-dimer, fibrinogen (Fg) and platel et al pha-granular membrane protein (GMP-140) were performed in 65 patients who had been on warfarin treatment for over one month. The patients were assigned to 3 groups on the basis of their International Normalized Ratios (INR), ranging from 2.00 to 2.50; 2.51 to 3.00; 3.01 to 4.50, respectively. The results showed that the D-dimer, Fg, GMP-140 levels were higher after mechanical valve replacement than those before operation, indicating the activation of coagulation and fibrinolysis system and the damage of platelets. Lower intensity anticoagulation therapy (INR 2.00 to 2.50) could effectively inhibit the activity of factor X and increase the level of AT III. There were no appreciable differences among D-dimer, Fg, GMP-140 and AT III in the 3 anticoagulation intensity groups. These results suggest that in patients with new generation mechanical prosthetic valves, target anticoagulation level (INR 2.00 to 2.50) may result in good protection from thrombo-embolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12840878     DOI: 10.1007/bf02895598

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  11 in total

Review 1.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

Authors:  P D Stein; J S Alpert; J Copeland; J E Dalen; S Goldman; A G Turpie
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

2.  Therapeutic ranges in anticoagulant administration.

Authors:  L Poller
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-08

Review 3.  Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation.

Authors:  E A Loeliger
Journal:  Acta Haematol       Date:  1985       Impact factor: 2.195

Review 4.  Thrombotic and bleeding complications of prosthetic heart valves.

Authors:  L H Edmunds
Journal:  Ann Thorac Surg       Date:  1987-10       Impact factor: 4.330

Review 5.  Thromboembolic complications of current cardiac valvular prostheses.

Authors:  L H Edmunds
Journal:  Ann Thorac Surg       Date:  1982-07       Impact factor: 4.330

6.  Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve.

Authors:  E G Butchart; P A Lewis; J A Bethel; I M Breckenridge
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

7.  Low-intensity anticoagulation in mechanical cardiac prosthetic valves.

Authors:  D B Wilson; M I Dunn; K Hassanein
Journal:  Chest       Date:  1991-12       Impact factor: 9.410

8.  Frequency of prosthetic valve-related complications with very low level warfarin anticoagulation combined with dipyridamole after valve replacement using St. Jude Medical prostheses.

Authors:  D Skudicky; M R Essop; T Wisenbaugh; J Skoularigis; A R Essop; A Dullabh; S Bedhesi; V Strugo; P Sareli
Journal:  Am J Cardiol       Date:  1994-12-01       Impact factor: 2.778

9.  Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis.

Authors:  D Horstkotte; H D Schulte; W Bircks; B E Strauer
Journal:  J Thorac Cardiovasc Surg       Date:  1994-04       Impact factor: 5.209

10.  Comparison of two levels of anticoagulant therapy in patients with substitute heart valves.

Authors:  R Altman; J Rouvier; E Gurfinkel; O D'Ortencio; R Manzanel; L de La Fuente; R G Favaloro
Journal:  J Thorac Cardiovasc Surg       Date:  1991-03       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.